A
Amaranth Medical
Bioresorbable scaffolds for interventional cardiology procedures
About Amaranth Medical
Amaranth Medical was a medical device company that developed a technology platform for fully bioresorbable scaffolds aimed at the interventional cardiology market. Founded in 2006 by F. Freddy Boey and S. Subbu Venkatraman, the Mountain View-based firm focused on creating coronary stents that could provide mechanical support to an artery after a procedure and then gradually and predictably dissolve, leaving the vessel healed and free from a permanent metal implant. The company's stated mission was to improve long-term patient health by eliminating the clinical limitations associated with permanent stents.
The company's product pipeline included several scaffolds with progressively thinner struts, designed to mimic the performance of best-in-class metallic drug-eluting stents. Key products included the FORTITUDE, APTITUDE, and MAGNITUDE scaffolds. The FORTITUDE scaffold, its lead product, was designed to offer the high radial strength of metal stents while being fully bioresorbable. Amaranth successfully completed first-in-human studies and several international clinical trials for its sirolimus-eluting scaffolds, such as RENASCENT-I, RENASCENT-II, and MEND-II, with plans to seek a CE mark for commercialization in Europe.
Throughout its operation, Amaranth Medical raised significant capital, including a $20 million Series B round in 2013 from investors such as EDBI, Charter Life Sciences, and Phillip Capital. In 2014, it secured an additional equity investment from Boston Scientific to further advance clinical development and pursue CE marking. The company was led by CEO and CTO Kamal Ramzipoor, who emphasized the unique capabilities of Amaranth's proprietary polymer technology in creating thinner, stronger, and more flexible scaffolds compared to competitors. Despite its technological advancements and promising clinical data, the company ceased operations, and its assets were sold in a negotiated sale during an Assignment for the Benefit of Creditors, which was finalized around February 2019.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Amaranth Medical is 110 monthly website visits, up 57.1% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
evidnetProvides evidence-based medicine to patients |
Seoul, South Korea | Operational | 50 | $29M | $34M |
AntegenesGenetic tests for personalized cancer risk prevention |
Tartu, Estonia | Operational | |||
Human Life CORDUmbilical cord-derived allogeneic cell therapy development |
Tokyo, Japan | Operational | |||
GLX AnalytixBringing personalized medicine to your health care |
Copenhagen, Denmark | Operational | |||
Save MedicalDigital Therapeutic, Mobile App, Diabetes |
Tokyo, Japan | Operational | |||
CamallergyOral immunotherapy treatments for food and peanut allergies |
Cambridge, United Kingdom | Operational | |||
FlomicsRNA liquid biopsy for early multi-cancer detection |
Barcelona, Spain | Operational | |||
Active IronHealthcare development company focused on optimizing established therapies through innovative science |
Cork, Ireland | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Amaranth Medical in the Mountain View ecosystem
The Amaranth Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Bio*One Capital
Series A4 investors entered at this stage
EDBI
Charter Life Sciences
PhillipCapital- DMDCP Management
Other known investors1 additional known investor
Massachusetts Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Amaranth Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Amaranth Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








